Why the study?
Does albuminuria predict cardiovascular outcomes and does losartan reduce albuminuria more than atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy?
Population
1,063 patients with diabetes, hypertension, and left ventricular hypertrophy
Comparison
Losartan vs Atenolol
Design
Cohort
Follow-up
mean 4.7 years
Authors
Loading...
May partly mediate losartan CV benefit via greater UACR reduction in diabetic LVH; leaves open causal confirmation in RCTs.
Does albuminuria predict cardiovascular outcomes and does losartan reduce albuminuria more than atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy?
In patients with diabetes, hypertension, and left ventricular hypertrophy, losartan reduces albuminuria more effectively than atenolol, which partially explains its superior cardiovascular benefits.
Ibsen et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: